Skip to content
The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular.It should be noted that these stocks are risky in nature, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Given this volatility, it can be difficult to gauge which healthcare stocks are primed to outperform. That’s where Wall Street analysts come in.Using TipRanks’ database, we identified three trading for less than $5 per share that not only earned a “Strong Buy” consensus rating from the analyst community, but also boasts triple-digit upside potential.Leap Therapeutics Inc. (LPTX)Developing...
(Bloomberg) -- WeWork cofounder Adam Neumann is seeking a buyer for his 11-acre property in Corte Madera, California, after paying $21.4 million for the estate in 2018.The home, located about 15 miles north of San Francisco, will be listed at $27.5 million, according to a person familiar with the matter, who requested anonymity because the deliberations are private.A spokesman for Neumann confirmed the potential sale.Neumann amassed multiple homes across the U.S., including New York, when WeWork was one of the most valuable startups on the planet. Now he’s entangled in a legal battle with SoftBank Group Corp. after the Japanese conglomerate walked from a deal that would’ve allowed him to sell shares worth up to $970 million.Located at 800 Corte Madera Avenue and known to some as ‘Guitar House’, the mansion is known for a living room that’s shaped like the musical instrument. Designed by architect Sim Van der Ryn, it...
(Bloomberg) -- A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, and is now set to move into larger trials that are likely to be decisive on how effective they truly are.The results weren’t enough to convince the market, however. AstraZeneca Plc fell from a record high in New York trading on concerns over whether its vaccine can match the progress seen in programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc.“In the competitive context they fail to impress,” said Bernstein analysts led by Ronny Gal.The vaccine increased levels of both protective neutralizing antibodies and immune T-cells that target the virus, according to the study organizers. The results, published Monday in The Lancet medical journal, are a key milestone for one of the fastest-moving vaccine projects globally.“Our hope is that we can actually start delivering a vaccine before...
Chuck Jones has been the CEO of FirstEnergy Corp. (NYSE:FE) since 2015, and this article will examine the executive's......
With the U.S. coronavirus case count zeroing in on 4 million, health experts ramped up their calls for a stronger federal leadership....
Wells Fargo Asset Management Multi-Asset Strategist Brian Jacobsen joins Yahoo Finance’s Akiko Fujita to discuss what to expect from upcoming earnings....
